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Abstract 
Background: Podocalyxin-like 1 (PODXL) is an anti-adhesive transmembrane protein that has been demonstrated 
to be an independent factor of poor prognosis in colorectal cancer (CRC). The gene encoding PODXL is located to 
chromosome 7, which also harbours the gene for the epidermal growth factor receptor (EGFR). The aim of this study 
was to examine the associations between PODXL and EGFR expression in CRC in vitro and in vivo.
Methods: EGFR expression was analysed in tumours from three independent patient cohorts; cohort 1 (n = 533), 
cohort 2 (n = 259) and cohort 3 (n = 310), previously analysed for immunohistochemical PODXL expression and KRAS 
and BRAF mutations (cohort 1 and 3). Levels of EGFR and PODXL were determined by western blot in six different CRC 
cell lines.
Results: High expression of PODXL was significantly associated with high EGFR expression (p < 0.001) in all three 
cohorts, and with BRAF mutation (p < 0.001) in cohort 1 and 3. High EGFR expression correlated with BRAF mutation 
(p < 0.001) in cohort 1. High EGFR expression was associated with adverse clinicopathological factors and indepen-
dently predicted a reduced 5-year overall survival (OS) in cohort 1 (HR 1.77; 95 % CI 1.27–2.46), cohort 2 (HR 1.58; 
95 % CI 1.05–2.38) and cohort 3 (HR 1.83; 95 % CI 1.19–2.81). The highest risk of death within 5 years was observed 
in patients with tumours displaying high expression of both EGFR and PODXL in cohort 1 and 3 (HR 1.97; 95 % CI 
1.18–3.28 and HR 3.56; 95 % CI 1.75–7.22, respectively). Western blot analysis showed a uniform expression of PODXL 
and EGFR in all six examined CRC cell lines.
Conclusions: The results from this study demonstrate that high expression of EGFR is an independent factor of 
poor prognosis in CRC. Moreover, strong links have been uncovered between expression of the recently proposed 
biomarker candidate PODXL with EGFR expression in CRC in vivo and in vitro, and with BRAF mutation in vivo. High 
expression of both PODXL and EGFR may also have a synergistic adverse effect on survival. These findings suggest a 
potential functional link in CRC between PODXL, EGFR and BRAF, all originating from chromosome 7, which may be 
highly relevant in the clinical setting and therefore merit future in-depth study.
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Background
Podocalyxin-like protein (PODXL) is a transmem-
brane glycoprotein and member of the CD34 family [1]. 
PODXL regulates cell adhesion and is normally expressed 
by podocytes of the kidney, vascular endothelial cells and 
hematopoietic progenitor cells [2–4]. Moreover, PODXL 
has been shown to be overexpressed in a variety of malig-
nancies, and associated with a more aggressive tumour 
phenotype and poor prognosis in breast, prostate, colo-
rectal, ovarian, renal, pancreatic and bladder cancer, 
as well as in glioblastoma and astrocytoma [5–14]. The 
adverse prognostic role of PODXL expression in colo-
rectal cancer (CRC) was first described only recently [7], 
and has since then been validated in several independent 
studies [15–17].
The exact mechanisms behind the role of PODXL in 
tumourigenesis are still unknown, but it has been dem-
onstrated to be involved in epithelial-mesenchymal tran-
sition (EMT), a process in which epithelial cells obtain 
mesenchymal properties leading to increased migration, 
invasiveness and resistance to apoptosis [18]. In two 
recent studies, knockdown of PODXL in breast cancer 
cell lines resulted in impaired primary tumour growth 
and metastasis [19, 20].
The gene encoding PODXL is located to chromosome 
7, which also harbours several other genes with impor-
tant implications in CRC, e.g. the genes encoding the epi-
dermal growth factor receptor (EGFR) and v-Raf murine 
sarcoma viral oncogene homolog B (BRAF). Of note, the 
PODXL and BRAF genes are located right next to each 
other at 7q32-33 and 7q34.
EGFR is a transmembrane receptor tyrosine kinase 
that plays an important role in CRC initiation and pro-
gression through the RAS–RAF–MEK- MAPK and the 
PI3K–PTEN–Akt signalling pathways. Overexpression of 
EGFR has been reported in 25–75 % of CRC [21].
The clinical significance of EGFR overexpression in 
CRC remains unclear. Whereas several studies have dem-
onstrated a link between high EGFR expression and poor 
prognosis [22–26], other studies have not found EGFR 
expression to correlate with an adverse outcome [22, 27, 
28]. However, due to its role in the progression of CRC, 
EGFR has become an interesting target for antitumoural 
therapy, and monoclonal anti-EGFR antibodies cetuxi-
mab and panitumumab are widely used in metastatic 
CRC [29].
The aim of this study was to investigate the relationship 
between PODXL and EGFR expression in CRC in  vivo 
and in vitro. To this end, immunohistochemical expres-
sion of the proteins was compared in tumours from three 
different patient cohorts, and western blot analysis was 
performed on six different CRC cell lines.
Methods
Patients
Cohort 1 encompasses tumours from incident CRC cases 
in the population-based, prospective cohort Malmö Diet 
and Cancer Study (MDCS). Until end of follow-up 31 
December 2008, 626 incident cases of CRC had been reg-
istered in the study population, and tumour tissue for tis-
sue microarray (TMA) was available from 557 patients. 
The cohort has been described previously [7, 30, 31].
Cohort 2 is a consecutive, retrospective cohort com-
prising all patients who underwent surgery for CRC at 
Skåne University Hospital in Malmö, Sweden between 1 
January 1990 and 31 December 1991, for whom archival 
tumour tissue was available (n  =  270). The cohort has 
been described previously [15, 32, 33].
Cohort 3 consists of 337 patients who were surgi-
cally treated for CRC at the Central District Hospital in 
Västerås, Sweden between August 2000 and December 
2003. TMAs were constructed from 320 patients. The 
cohort has been described previously [15, 32, 34].
Patient and tumour characteristics in the different 
cohorts are summarized in Additional file 1.
Approvals for the study were obtained from the Ethics 
Committees at Lund University (ref 51/90, 530/08 and 
445/2007) and Uppsala University (ref 00/001).
PODXL and EGFR immunohistochemistry and evaluation
Formalin-fixed, paraffin-embedded CRC tissue blocks 
were used to construct TMAs as previously described 
[7], and immunohistochemical staining was performed 
on 4 μm TMA-sections.
PODXL expression has previously been analysed in all 
three cohorts [7, 15]. In brief, the affinity-purified poly-
clonal anti-PODXL antibody HPA 2110 (Atlas Antibod-
ies, Stockholm, Sweden), diluted 1:250 was used, and 
staining was performed in an Autostainer Plus (Dako, 
Glostrup, Denmark) after automated pre-treatment 
with the PT-link system (Dako). PODXL expression was 
denoted as negative (0), weak cytoplasmic staining (1), 
moderate cytoplasmic staining (2), distinct membranous 
staining in ≤50 % of tumour cells (3) and distinct mem-
branous staining in > 50 % of tumour cells (4), as previ-
ously described [7]. Based on the presence or absence of 
membranous staining, PODXL expression was dichot-
omised into low (0–2) or high (3–4).
For immunohistochemical analysis of EGFR, TMA-
sections were automatically pre-treated using the PT-link 
system (DAKO, Glostrup, Denmark) and then stained in 
an Autostainer Plus (DAKO, Glostrup, Denmark) with 
the monoclonal antibody 31G7 (Zymed Laboratories Inc, 
San Francisco, CA, USA, diluted 1:25). For validatory 
purposes, TMAs from cohort 1 were also stained with 
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the primary anti-EGFR antibody 3C6 (Ventana Medi-
cal Systems, Tucson, AZ, USA), stained in a BenchMark 
ULTRA (Ventana Medical Systems). Antigen retrieval 
was performed with protease1 (Ventana Medical Sys-
tems) for 8 min and antibody incubation time was 32 min 
in 36 °C. EGFR expression was determined by the inten-
sity (0–3) of membranous staining in tumour cells in line 
with the scoring protocol proposed by Goldstein [21]. A 
score of 0–1 was considered low EGFR expression, and 
2–3 indicated high EGFR expression.
Assessment of PODXL and EGFR expression was per-
formed in the same way for all three cohorts by two inde-
pendent observers (AL and KJ). Interobserver differences 
were discussed in order to reach consensus.
Analysis of KRAS and BRAF mutation status
The PyroMark Q24 system (Qiagen GmbH, Hilden, Ger-
many) was used for pyrosequencing analysis of KRAS 
and BRAF mutations in DNA from 1 mm formalin-fixed, 
paraffin-embedded or fresh frozen tumour tissue cores 
taken from areas with >90 % tumour cells, as previously 
described [35]. In brief, DNA was isolated from tumour 
tissue using QIAamp MinElute spin columns (Qiagen) 
and DNA regions of interest were PCR-amplified (Veriti 
96-Well Fast Thermal Cycler, Applied Biosystems Inc., 
Foster City, CA, USA).
Detection of mutations in KRAS codons 12 and 13 
was performed using Therascreen KRAS Pyro Kit (Qia-
gen). Analysis of BRAF mutation hotspots in codons 
600 and 601 was performed using previously pub-
lished PCR primers (Richman, JCO 2009) and a novel 
BRAF sequencing primer (5′-TGATTTTGGTCTAGCT 
ACA-3′) which was designed using the PyroMark Assay 
Design 2.0 software (Qiagen). All samples with a poten-
tial low-level mutation were re-analysed.
Cell culture
CRC cell lines Caco-2, RKO, SW480, SW620, HCT-116 
and HT-29 were used and maintained in a humified 
atmosphere at 37  °C and 5  % carbon dioxide/95  % air. 
Caco-2 and RKO cell lines were grown in EMEM supple-
mented with 2 mM l-glutamine, 10 % FBS (fetal bovine 
serum) and 1XPEST (penicillin 90  IU/ml and strepto-
mycin 90  µg/ml). SW480 and SW620 were maintained 
in DMEM with 4  mM l-glutamine, 4500  mg/L glucose, 
1  mM sodium pyruvate, 10  % FBS and 1XPEST, while 
HCT-116 and HT-29 were grown in McCoy’s 5A medium 
supplemented with 1.5 mM l-glutamine, 2.2 g/L sodium 
bicarbonate, 10 % FBS and 1XPEST.
Western blot
The levels of EGFR and PODXL in cell lines were deter-
mined by western blot. To check for basal levels of the 
proteins, cells were harvested when still sub-confluent. 
For western blot analysis, cells were trypsinised and 
washed in PBS. Cell pellets were kept at −80  °C for at 
least 24  h after which they were lysed in RIPA buffer 
(Sigma-Aldrich Co, St Louis, MO, cat #R0278: 150 mM 
NaCl, 1.0 % IGEPAL® CA-630, 0.5 % sodium deoxycho-
late, 0.1 % SDS, 50 mM Tris, pH 8.0), supplemented with 
protease inhibitors and phos-STOP (Roche, Basel, Swit-
zerland). Lysates were centrifuged at 4  °C for 10  min at 
6200  g and supernatants collected. Protein concentra-
tions were determined using the BCA Protein Assay 
(Thermo Scientific, Rockford, IL). Twenty µg of protein 
was separated on 4–15  % graded Mini-PROTEAN® 
TGX™ precast gels (Bio-Rad Laboratories Inc. Hercules, 
CA). For PODXL blots, an XCell SureLock® Mini-Cell 
(Thermo Scientific, Rockford, IL) wet transfer system 
was used (25 V for 2 h) with a transfer buffer containing 
25 mM Tris base, 192 mM glycine, 20 % ethanol at a pH 
of 8.3. PVDF membranes were activated for 30 s in 99.5 % 
ethanol before transfer sandwich assembly. For EGFR 
blots, the Trans-Blot® Turbo™ Mini PVDF Transfer 
packs were used together with the Trans-Blot® Turbo™ 
Transfer System (Bio-Rad Laboratories Inc. Hercules, 
CA). Membranes were subsequently blocked with 5  % 
non-fat dry milk in TBS-tween 0.1  % and probed with 
the following antibodies overnight: EGFR (Cell Signaling 
Inc., Danvers, MA, cat#4267, dilution 1:1000), PODXL 
(Atlas Antibodies, cat#HPA002110, 1:500) and actin 
(Santa Cruz Biotechnology Inc., Dallas, TX, cat#sc-1616, 
1:1000). Three sets of lysates were prepared and blotted 
for every cell line, and one representative experiment is 
shown.
Cell pellet array and immunocytochemistry
Cell lines were trypsinised and washed in PBS. Subse-
quently, cell pellets were fixed in formalin for at least 
24 h followed by staining with Mayer’s haematoxylin for 
5 min. Cells were washed once in PBS and dehydrated in 
graded ethanol series after which cell pellets were washed 
in molten paraffin several times. Cell pellets were arrayed 
in duplicate or triplicate 1.0 mm cores using a semi-auto-
mated arraying device (TMArrayer; Pathology Devices, 
Inc., Westminster, MD). Immunohistochemistry was per-
formed on 5 µm sections using the same antibodies as for 
western blot with the following dilutions: EGFR, 1:100 
and PODXL, 1:500. Images were captured at 20X using 
the cellSens entry software (version 1.8, Olympus).
Statistical analysis
The Chi square test was applied for comparison of 
PODXL expression with EGFR expression and molecular 
characteristics, and for comparison of EGFR expression 
with established prognostic clinicopathological factors. 
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Kaplan–Meier analysis and log rank test were applied to 
illustrate differences in 5-year OS according to PODXL 
and EGFR expression. Cox’s proportional hazards regres-
sion was used for estimation of hazard ratios (HR) for 
death from CRC within 5 years, according to PODXL and 
EGFR expression in both univariable and multivariable 
analysis adjusted for age, sex, T-, N-, M-stage, differen-
tiation grade and vascular invasion. Co-variables were 
entered into the multivariable analysis using backward 
selection where a p value of 0.05 decided entry and a 
p-value of 0.10 was used for removal. All tests were two-
sided. A p value of 0.05 was considered significant. All 
statistical analyses were performed using SPSS version 
20.0 (SPSS Inc, Chicago, IL).
Results
Overexpression of PODXL is associated with EGFR 
expression and BRAF mutation in colorectal cancer
EGFR could be analysed in 533/626 (85.1  %) cases in 
cohort 1, 259/270 (95.9 %) cases in cohort 2, and 310/337 
(92.0 %) cases in cohort 3. Sample immunohistochemical 
images are shown in Fig. 1.
The intercorrelation between PODXL and other inves-
tigative factors are shown in Table  1. High expression 
of PODXL was significantly associated with high EGFR 
expression (p < 0.001) in all three cohorts, and with BRAF 
mutation (p < 0.001) and MSI (p < 0.001 and p = 0.021 
respectively) in cohort 1 and 3. There was no significant 
correlation between PODXL expression and KRAS muta-
tion (cohort 1 and 3). Information on BRAF status, MSI 
and KRAS mutation was not available in cohort 2.
Associations of EGFR expression with established 
clinicopathological and investigative factors are shown 
in Table  2. In cohort 1 and 3, high EGFR expression 
was significantly associated with more advanced T-, N-, 
M-stage, low differentiation grade and vascular invasion. 
In cohort 2, there was a significant association between 
high EGFR expression and M-stage. Furthermore, high 
EGFR expression was significantly associated with BRAF 
mutation in cohort 1 (p < 0.001).
As further shown in Additional file 2, there was a very 
good correlation between EGFR protein expression 
assessed by both antibodies in cohort 1.
Overexpression of EGFR is associated with a poor 
prognosis, in particular in combination with PODXL 
overexpression
Kaplan–Meier analysis showed that high EGFR expres-
sion, in particular in combination with high PODXL 
expression, correlated with a reduced overall survival in 
all three cohorts (Fig. 2). As shown in Table 3, high EGFR 
expression was an independent predictor of a reduced 
5-year OS in cohort 1 (HR 1.77; 95  % CI 1.27–2.46), 
cohort 2 (HR 1.58; 95 % CI 1.05–2.38) and cohort 3 (HR 
1.83; 95 % CI 1.19–2.81). The highest risk of death within 
5 years was observed in patients with tumours displaying 
high expression of both EGFR and PODXL in cohort 1 
and 3 (unadjusted HR 1.97; 95  % CI 1.18–3.28 and HR 
3.56; 95 % CI 1.75–7.22, respectively), remaining signifi-
cant in adjusted analysis in cohort 3 (HR 3.71; 95  % CI 
1.23–11.20). P values for term of interaction between 
EGFR and PODXL in cohort 1, 2 and 3 were 0.114, 0.690 
and 0.147 respectively. In cohort 2, high PODXL expres-
sion was an independent prognostic factor in patients 
with tumours displaying low but not high EGFR expres-
sion (unadjusted HR 2.02; 95  % CI 1.02–4.02) and 
adjusted HR 2.59; 95 % CI 1.26–5.31).
PODXL and EGFR levels in colorectal cancer cell lines
As shown in Fig.  3, western blot analysis demon-
strated that all cell lines with expression of PODXL also 
expressed EGFR, whereas the cell lines without PODXL 
expression did not. In cell lines derived from the same 
Fig. 1 Sample immunohistochemical images. Immunohistochemical 
image of a colorectal tumour with high expression of both EGFR and 
PODXL. Note the subset of infiltrative cells with particularly strong 
membranous expression of both proteins
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Table 2 Associations of EGFR status with clinicopathological characteristics in three independent CRC patient cohorts
Kruskal–Wallis or Mann–Whitney U test applied for continuous variables
MSI microsatellite instability; MSS microsatellite stable
EGFR Cohort 1 p value Cohort 2 p value Cohort 3 p value
Low High Low High Low High
N (%) 419 (78.6) 114 (21.4) 202 (78.0) 57 (21.1) 259 (83.5) 51 (16.5)
Age
 Mean, median 70.6, 71.4 69.9, 71.3 0.439 72.6, 73.5 70.7, 73.1 0.401 71.1, 73.0 71.5, 74.0 0.977
 Range 51.3–85.6 49.8–83.5 37.6–92.1 37.8–93.3 36.0–94.0 50.0–87.0
Sex
 Female 219 (52.3) 62 (54.4) 0.688 98 (48.5) 34 (59.6) 0.138 129 (49.8) 29 (56.9) 0.358
 Male 200 (47.7) 52 (45.6) 104 (51.5) 23 (40.4) 130 (50.2) 22 (43.1)
Location
 Colon 258 (61.9) 76 (66.7) 0.348 161 (79.7) 48 (85.7) 0.311 177 (68.3) 30 (58.8) 0.188
 Rectum 159 (38.1) 38 (33.3) 41 (20.3) 8 (14.3) 82 (31.7) 21 (41.2)
 Missing 2
T-stage
 T1 43 (10.9) 1 (0.9) <0.001 14 (7.1) 4 (7.1) 0.432 11 (4.2) 0 (0.0) 0.002
 T2 55 (13.9) 7 (6.2) 53 (26.8) 11 (19.6) 38 (14.7) 1 (2.0)
 T3 249 (62.9) 75 (67.0) 107 (54.0) 33 (58.9) 169 (65.3) 37 (72.5)
 T4 49 (12.4) 29 (25.9) 24 (14.3) 8 (14.3) 41 (15.8) 13 (25.5)
 Missing 23 2 4 1
N-stage
 N0 232 (61.7) 48 (43.2) 0.002 129 (64.8) 33 (61.1) 0.331 164 (63.39 18 (35.3) <0.001
 N1 87 (23.1) 34 (30.6) 50 (25.1) 12 (22.2) 53 (20.5) 9 (17.6)
 N2 57 (15.2) 29 (26.1) 20 (10.1) 9 (16.7) 42 (16.2) 24 (47.1)
 Missing 43 3 3 3
M-stage
 M0 349 (84.5) 82 (72.6) 0.003 180 (89.6) 40 (72.7) 0.002 232 (89.6) 39 (76.5) 0.010
 M1 64 (15.5) 31 (27.4) 21 (10.4) 15 (27.3) 27 (10.4) 12 (23.5)
 Missing 6 1 1 2
Diff. grade
 High 28 (6.8) 4 (3.6) <0.001 16 (7.9) 5 (8.8) 0.402 8 (3.1) 1 (2.0) 0.006
 Intermediate 310 (75.4) 62 (55.4) 138 (68.3) 34 (59.6) 202 (78.0) 31 (60.8)
 Low 73 (17.8) 46 (41.1) 48 (23.8) 18 (31.6) 49 (18.9) 19 (37.3)
 Missing 8 2
Vasc. invasion
 No 125 (53.2) 27 (34.2) 0.003 108 (54.8) 24 (44.4) 0.177 233 (90.0) 38 (74.5) 0.002
 Yes 110 (46.8) 52 (65.8) 89 (45.2) 30 (55.6) 26 (10.0) 13 (25.5)
 Missing 184 35 5 3
MSI status
 MSS 333 (85.4) 85 (81.0) 0.266 N/A N/A 214 (82.9) 47 (92.2) 0.098
 MSI 57 (14.6) 20 (19.0) N/A N/A 44 (17.1) 4 (7.8)
 Missing 29 9 1
KRAS status
 Wild-type 253 (63.9) 66 (61.1) 0.596 N/A N/A 108 (63.5) 24 (70.6) 0.433
 Mutated 119 (36.1) 42 (38.9) N/A N/A 62 (36.5) 10 (29.4)
 Missing 23 6 89 17
BRAF status
 Wild-type 348 (88.1) 78 (72.2) <0.001 N/A N/A 152 27 0.147
 Mutated 47 (11.9) 30 (27.8) N/A N/A 27 9
 Missing 24 6 80 15
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patient, EGFR and PODXL were expressed in the pri-
mary tumour cell line (SW480), but not in the metastatic 
derivative (SW620).
Discussion
Chromosome 7 harbours several genes of importance 
in CRC, e.g. EGFR, PODXL and BRAF [36]. The results 
from the present study, based on analyses of tumours 
from more than 1100 patients, demonstrate, for the 
first time, strong significant associations between high 
protein expression of PODXL and EGFR in CRC. In 
the two largest examined cohorts, where data on BRAF 
mutation and MSI status was available for the majority 
of cases, PODXL expression was also found to correlate 
Fig. 2 Kaplan–Meier analysis. Kaplan-Meier estimates of 5-year OS according to combinations of PODXL and EGFR expression in cohort 1 (a), 
cohort 2 (b) and cohort 3 (c). Log rank p values correspond to pairwise comparisons of colorectal tumours with low expression of PODXL and EGFR 
with the other strata
Table 3 Cox regression analysis of relative risks of death within 5 years according to EGFR and PODXL expression in colo-
rectal cancer
Cohort 1 and 2 adjusted for age at surgery, sex, PODXL, EGFR, T-, N-, M-stage, differentiation grade and vascular invasion in multivariable analysis
Cohort 3 adjusted for age at surgery, sex, PODXL, EGFR, T-, N-, M-stage, differentiation grade, vascular invasion and neural invasion in multivariable analysis
Cohort 1 Cohort 2 Cohort 3
HR (95 % CI) HR (95 % CI) N (events) HR (95 % CI) HR (95 % CI) N (events) HR (95 % CI) HR (95 % CI) N 
(events)
Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
All
 EGFR low 1.00 1.00 419 (146) 1.00 1.00 202 (101) 1.00 1.00 259 (88)
 EGFR high 1.82 (1.35–2.46) 1.77 (1.27–2.46) 114 (61) 1.98 (1.39–2.84) 1.58 (1.05–2.38) 57 (43) 2.60 (1.74–3.89) 1.83 (1.19–2.81) 51 (33)
All
 PODXL low 1.00 1.00 464 (168) 1.00 1.00 235 (123) 1.00 1.00 291 (103)
 PODXL high 1.73 (1.21–2.46) 1.16 (0.77–1.73) 72 (38) 2.27 (1.43–3.62) 1.91 (1.11–3.27) 25 (21) 3.45 (2.13–5.58) 1.23 (0.68–2.22) 25 (20)
EGFR low
 PODXL low 1.00 1.00 373 (128) 1.00 1.00 183 (89) 1.00 1.00 247 (82)
 PODXL high 1.06 (0.58–1.91) 0.87 (0.45–1.66) 34 (12) 2.02 (1.02–4.02) 2.59 (1.26–5.31) 12 (9) 1.62 (0.65–3.99) 0.74 (0.28–1.95) 10 (5)
EGFR high
 PODXL low 1.00 1.00 75 (35) 1.00 1.00 44 (31) 1.00 1.00 37 (19)
 PODXL high 1.97 (1.18–3.28) 1.38 (0.71–2.68) 37 (26) 1.60 (0.80–3.21) 1.69 (0.74–3.84) 12 (11) 3.56 (1.75–7.22) 3.71 (1.23–11.20) 14 (14)
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Fig. 3 Western blot and immunocytochemical analysis of EGFR and PODXL in CRC cells. a Western blot and b immunocytochemical analysis of 
PODXL and EGFR protein levels in six different CRC cell lines; Caco-2, SW480, SW620, HCT-116, RKO and HT-29
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with BRAF mutation and MSI. The correlation between 
PODXL and EGFR was further demonstrated in  vitro, 
with the proteins being uniformly expressed in six differ-
ent CRC cell lines.
Moreover, the results from this study, based on immu-
nohistochemical analysis of tumours from three inde-
pendent patient cohorts, demonstrate that high EGFR 
protein expression is an independent negative prognostic 
factor in CRC patients. Despite diverging results in the 
literature regarding the prognostic significance of EGFR, 
these findings are in line with several previous studies, 
wherein EGFR protein expression has been associated 
with advanced disease stage [37, 38] and poor survival 
[39–42], hence adding further weight to the feasibility of 
EGFR as a negative prognostic biomarker in CRC.
Of note, the herein used anti-EGFR antibody was vali-
dated against another antibody, showing high concord-
ance. These antibodies from Zymed and Ventana have 
also been demonstrated to perform better than others 
[43].
Expression of PODXL has previously been shown to 
be an independent adverse prognostic factor in all three 
herein investigated cohorts [7, 15]. In cohort 1 and 3, 
the worst prognosis was seen in patients with tumours 
displaying high expression of both EGFR and PODXL. 
This observation indicates that there may be a syner-
gistic adverse prognostic effect of PODXL and EGFR, 
even if there was no significant interaction. Moreover, 
the results from cohort 2 differed somewhat in that high 
EGFR expression was an independent prognostic factor 
in PODXL low, but not high, tumours. Of note, in cohort 
2, with exception for M-stage, there were no significant 
associations of EGFR expression with established unfa-
vourable clinicopathological factors, whereas in cohort 1 
and 3, high EGFR expression was significantly associated 
with more advanced T-, N- and M-stage, low differentia-
tion grade and vascular invasion. In contrast to EGFR, 
high PODXL expression was found to correlate with 
more advanced N-stage, low differentiation grade and 
vascular invasion in cohort 2 [15].
Management of CRC has improved immensely over the 
past decades due to refined surgical techniques and opti-
mal use of chemotherapy. The introduction of targeted 
therapies including bevacizumab and anti-EGFR anti-
bodies has further improved outcome for patients with 
metastatic CRC. Disease stage is still the strongest prog-
nostic factor, however, in this era of personalised medi-
cine, new classification systems based on prognostic and 
predictive markers are needed to select the most efficient 
treatment for patients. In recent years, different research 
groups have proposed new classification systems based 
on gene expression in colorectal tumours [44–46]. Inde-
pendently, all groups have indentified one subtype that is 
associated with EMT, poor differentiation and unfavora-
ble prognosis. EMT is considered a critical step in the 
progression to metastasis, and PODXL plays an impor-
tant role in this process [18].
KRAS, NRAS and BRAF mutation status is used as 
predictive markers for response to treatment with mon-
oclonal anti-EGFR antibodies. However, only approxi-
mately 40  % of CRC patients with tumours wild-type 
for KRAS, NRAS and BRAF benefit from such therapy 
[47–50], and patients who initially respond eventu-
ally become resistant to these drugs. Several potential 
mechanisms of acquired resistance to anti-EGFR drugs 
have been proposed, one of them being EMT. Evidence 
suggests that EGFR signalling can trigger EMT [51], 
but once EMT is established, signalling associated with 
EGFR activation is reduced [52]. Moreover, studies on 
non-small cell lung cancer (NSCLC) and CRC cell lines 
have shown that tumour cells that have undergone EMT 
are much less sensitive to anti-EGFR treatment [53, 54]. 
In a study by Buck et al., CRC cell lines derived from the 
same patient showed epithelial characteristics and sensi-
tivity to EGFR tyrosine kinase inhibitor erlotinib in cells 
from the primary tumour, whereas tumour cells from the 
liver metastasis exhibited a mesenchymal phenotype and 
were not sensitive to erlotinib [54]. Interestingly, in our 
study, using the same cell lines, EGFR and PODXL were 
expressed in cells from the primary tumour, but not in 
the metastatic cell line. Thus, EMT, and possibly PODXL, 
may have a role in resistance to anti-EGFR drugs by acti-
vating alternative signalling pathways.
Moreover, previous in  vitro studies have shown 
that expression of PODXL leads to recruitment of the 
Na +/H +  Exchanger Regulatory Factor (NHERF) pro-
teins to the apical domain of the epithelial cell [55]. 
NHERF-1 in turn has been shown to stabilise EGFR at 
the cell surface to restrict receptor downregulation, thus 
enhancing EGFR signalling [56]. Based on these results it 
would be of interest to investigate whether PODXL may 
affect the response to monoclonal anti-EGFR antibody 
therapy by limiting the downregulation of EGFR recep-
tors through NHERF-1.
Conclusions
The results from this study demonstrate that high 
expression of EGFR is an independent factor of poor 
prognosis in CRC. Moreover, strong links have been 
uncovered between expression of the recently proposed 
biomarker candidate PODXL with EGFR expression 
in CRC in  vivo and in  vitro, and with BRAF mutation 
in vivo. High expression of both PODXL and EGFR may 
also have a synergistic adverse effect on survival. Taken 
together, these findings suggest a functional link in CRC 
between PODXL, EGFR and BRAF, all originating from 
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chromosome 7. Future in-depth studies are warranted to 
further elucidate the mechanistic basis underlying these 
observations, which may be highly relevant in the clinical 
setting.
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